Glucuronyl Glucosyloleanolate: Discovery and Evaluation of a Skin Depigmenting Compound

Background Growing regulatory and safety limitations of established tyrosinase inhibitors create an unmet need for safer, mechanistically distinct depigmenting agents. Glucuronyl Glucosyloleanolate (GGO), a natural saponin, was identified through an AI‐enabled discovery platform integrating public compound databases with in silico physicochemical and toxicity predictions. Methods GGO was evaluated in normal human epidermal melanocyte (NHEM) models for melanin inhibition and tyrosinase activity. Ex vivo activity was assessed in UV‐stimulated NativeSkin human skin explants. Safety was evaluated by semi‐occlusive patch test ( n = 12) and a validated GARDskin assay (OECD 442E). Clinical efficacy was assessed in a randomized, single‐blind, placebo‐controlled trial ( n = 60; 84 days; 0.01% twice‐daily application), stratified by Fitzpatrick phototype. Results GGO inhibited melanin production by up to 86% at 2 µg/mL in NHEMs, outperforming hydroquinone, kojic acid, niacinamide, and tranexamic acid. GGO did not directly inhibit tyrosinase, indicating a distinct mechanism. In UV‐stimulated explants, melanin content decreased 45% and tyrosinase expression by 2.4‐fold. No irritation (mean irritation index 0.00) or sensitization potential was detected. Clinically, GGO produced statistically significant increases in Individual Typology Angle (ITA°) from Day 21: 11% in phototype III, 14% in phototype IV, and 24% in phototype V at Day 84. Conclusions GGO is a safe and effective depigmenting ingredient with a differentiated, multi‐target mechanism of action. These data support its use as a clinically validated cosmetic active for skin brightening and hyperpigmentation management.